MEI Pharma (FRA:MMI0) Change In Inventory : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is MEI Pharma Change In Inventory?

MEI Pharma's change in inventory for the quarter that ended in Mar. 2024 was €0.00 Mil. It means MEI Pharma's inventory stayed the same from Dec. 2023 to Mar. 2024 .

MEI Pharma's change in inventory for the fiscal year that ended in Jun. 2023 was €0.00 Mil. It means MEI Pharma's inventory stayed the same from Jun. 2022 to Jun. 2023 .

MEI Pharma's Total Inventories for the quarter that ended in Mar. 2024 was €0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MEI Pharma Change In Inventory Historical Data

The historical data trend for MEI Pharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MEI Pharma Change In Inventory Chart

MEI Pharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Change In Inventory

Get a 7-Day Free Trial

MEI Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

MEI Pharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

MEI Pharma (FRA:MMI0) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

MEI Pharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

MEI Pharma's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

MEI Pharma's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

MEI Pharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of MEI Pharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

MEI Pharma (FRA:MMI0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (FRA:MMI0) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

MEIP:USA

Address

11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130

Website

https://www.meipharma.com

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

MEI Pharma (FRA:MMI0) Headlines

No Headlines